Issue
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
Identification of a recurrent mutation in the protoporphyrinogen oxidase gene in swiss patients with variegate porphyria: Clinical and genetic implications
Corresponding Author(s) : A M Van TuylL Van Serooskerke
am.van.tuyll@mumc.nl
Cellular and Molecular Biology,
Vol. 55 No. 2: Porphyrias and associated pathologies. Biochemistry and molecular biology Part 2
Abstract
Variegate porphyria (VP), one of the acute hepatic porphyrias, results from an autosomal dominantly inherited deficiency of protoporphyrinogen oxidase (PPOX), the seventh enzyme in heme biosynthesis. Affected individuals can develop both cutaneous symptoms and potentially life-threatening neurovisceral attacks. Thirty unrelated VP index patients and families are currently known in the Swiss Porphyrin Reference Laboratory in Zürich. In 16 of a total of 24 genetically tested families, we detected a recurrent mutation in the PPOX gene, designated 1082-1083insC, reflecting a prevalence of 67%. Haplotype analysis revealed that 1082-1083insC arose on a common genetic background and, thus, represents a novel founder mutation in the Swiss population. Knowledge on the carrier status within a family does not only allow for adequate genetic counseling but also for prevention of the potentially life-threatening acute porphyric attacks. Hence, future molecular screening in Swiss VP patients might be facilitated by first seeking for mutation 1082-1083insC.
Keywords
Porphyria
variegate porphyria
protoporphyrinogen oxidase gene
recurrent mutation
Switzerland
haplotyping
founder mutation.
Van TuylL Van Serooskerke, A. M., Schneider-Yin, X., Schimmel, R. J., Bladergroen, R. S., Barman, J., Poblete-Gutiérrez, P., Van Geel, M., Frank, J., & Minder, E. I. (2009). Identification of a recurrent mutation in the protoporphyrinogen oxidase gene in swiss patients with variegate porphyria: Clinical and genetic implications. Cellular and Molecular Biology, 55(2), 96–101. Retrieved from http://mail.cellmolbiol.org/index.php/CMB/article/view/1093
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX